Yield10 Bioscience (NASDAQ:YTEN) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Yield10 Bioscience (NASDAQ:YTENGet Rating) posted its earnings results on Wednesday. The specialty chemicals company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.03), MarketWatch Earnings reports. Yield10 Bioscience had a negative return on equity of 56.52% and a negative net margin of 1,796.58%. During the same period last year, the business earned ($0.60) earnings per share.

Shares of NASDAQ:YTEN opened at $2.08 on Friday. The business’s fifty day moving average price is $4.09 and its two-hundred day moving average price is $4.50. Yield10 Bioscience has a fifty-two week low of $1.91 and a fifty-two week high of $10.10. The stock has a market capitalization of $10.18 million, a price-to-earnings ratio of -0.89 and a beta of 1.54.

A hedge fund recently raised its stake in Yield10 Bioscience stock. Geode Capital Management LLC grew its holdings in Yield10 Bioscience, Inc. (NASDAQ:YTENGet Rating) by 10.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 43,381 shares of the specialty chemicals company’s stock after purchasing an additional 3,948 shares during the quarter. Geode Capital Management LLC owned about 0.89% of Yield10 Bioscience worth $213,000 as of its most recent filing with the SEC. 17.79% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages have commented on YTEN. Maxim Group dropped their price target on Yield10 Bioscience from $18.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, March 10th. Univest Sec began coverage on Yield10 Bioscience in a research report on Tuesday, May 3rd. They issued a “buy” rating on the stock. Zacks Investment Research raised Yield10 Bioscience from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, Lake Street Capital began coverage on Yield10 Bioscience in a research report on Thursday, April 21st. They issued a “buy” rating and a $12.00 price target on the stock.

Yield10 Bioscience Company Profile (Get Rating)

Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada. The company, through its Trait Factory, a trait gene discovery platform develops enhanced oilseed Camelina sativa for the production of proprietary seed products; and discovers high value genetic traits for the agriculture and food industries.

Featured Articles

Earnings History for Yield10 Bioscience (NASDAQ:YTEN)

Want More Great Investing Ideas?

Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.